Latest Regulatory Milestones News

Chalice Mining’s Pre-Feasibility Study confirms the Gonneville Project as a globally significant palladium-nickel-copper mine in Western Australia, boasting robust returns and a rapid payback period.

Chimeric Therapeutics has won FDA Orphan Drug Designation for its CHM CDH17 CAR-T therapy targeting gastric cancer, advancing its clinical development with regulatory incentives and potential market exclusivity.

Emerald Resources has secured mining approval for its Dingo Range Gold Project in Western Australia and completed a major accommodation camp, marking significant progress toward its goal of becoming a multi-mine gold producer.

Island Pharmaceuticals has submitted critical responses to the FDA, advancing the development of its antiviral Galidesivir under the Animal Rule pathway. The company awaits FDA feedback expected by early January 2026, setting the stage for upcoming Marburg virus studies.

MGX Resources has received Foreign Investment Review Board approval to acquire a 50% interest in the Central Tanami Gold Project, marking a pivotal step toward becoming a long-life Australian gold producer.

Beetaloo Energy has secured crucial Federal Ministerial approval to sell appraisal gas from its EP187 exploration project, moving closer to final Northern Territory Government endorsement.

Jameson Resources has locked in a $3 million capital raise from strategic investor King George Investments to advance its Crown Mountain coal project in British Columbia. The placement, priced at a 16.7% discount, underscores growing confidence in the project’s regulatory progress and market potential.

Black Cat Syndicate has entered a joint venture with Dreadnought Resources to develop and process ore from the high-grade Star of Mangaroon deposit, aiming to boost production and operational flexibility at its Paulsens facility.

Meteoric Resources NL has had its trading suspension lifted following its response to media speculation about the Preliminary License approval process, reopening investor access to its shares.

Renergen Limited and ASP Isotopes Inc. have secured crucial regulatory approvals and agreed to extend the deadline for completing their Scheme of Arrangement to January 2026, signaling steady progress in their strategic partnership.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Southern Cross Gold has secured approval for its underground exploration tunnel at the Sunday Creek project, marking a pivotal step towards mine development and enhanced resource definition.